

Promising Investigational Agents and Strategies for Patients with Metastatic Non-Small Cell Lung Cancer Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Investigation of the anti-TROP2 antibody-drug conjugate datopotamab deruxtecan for patients with advanced non-small cell lung cancer (NSCLC) in the TROPION-PanTumor01 trial revealed which dose yielded the best duration of response?**
  - 4 mg/kg
  - 6 mg/kg**
  - 8 mg/kg
- Which of the following best represents the difference in objective response rate (ORR) between plinabulin with docetaxel and docetaxel alone for patients with advanced NSCLC as reported in the DUBLIN-3 study?**
  - ORR with plinabulin was approximately half that of docetaxel
  - ORR with plinabulin was approximately double that of docetaxel**
  - ORR with plinabulin was approximately three times that of docetaxel
- Which of the following is not a known effect of tumor treating fields?**
  - Autophagy induction
  - Cell cycle arrest
  - Upregulation of immune checkpoint genes**
  - Downregulation of FA/BRCA genes
- Which of the following Grade 4 adverse events was significantly decreased with plinabulin for patients with advanced NSCLC in the DUBLIN-3 trial?**
  - Diarrhea
  - Rash
  - Retinal toxicity
  - Neutropenia**
- In the KEYNOTE-146 trial, treatment-emergent adverse events leading to dose reduction or interruption in patients with metastatic NSCLC were highest with which agent?**
  - Lenvatinib**
  - Atezolizumab
  - Pembrolizumab
  - Plinabulin